Startups
LS CancerDiag Ltd is committed to reducing cancer mortality rates with a simple diagnostic method that reliably detects an inherited cancer-causing condition prior to cancer. Our vision is to see DiagMMR® as the new Gold Standard for Lynch syndrome detection.
Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS.
Our groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC).
Our mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome globally by delivering predictive and accurate results with a fast, unique and cost-efficient method.
Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS.
Our groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary NonPolyposis Colorectal Cancer; HNPCC).
Our mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome globally by delivering predictive and accurate results with a fast, unique and cost-efficient method.
Overview
Location
Finland, Mainland Finland, Helsinki
Employees
1-10
Founded date
2013
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 31, 2016 | StartUp Health adds five companies to its new Finland program | Digital health accelerator StartUp Health launched its first regional affiliate program last November, a collaboration with Finpro, Finland’s Trade and Investment Promotion Agency. Now the program, StartUp Health Finland, has announced its ... |
Reviews 0
FAQ about LS CancerDiag
When was LS CancerDiag founded?
LS CancerDiag was founded in 2013.
What has the press written about LS CancerDiag?
Parsers VC has collected 2 articles mentioning LS CancerDiag, among them “StartUp Health adds five companies to its new Finland program” (May 31, 2016).
Is LS CancerDiag still active?
Yes, LS CancerDiag is active; its latest activity on Parsers VC dates from May 31, 2016.